Best Cardiac and Vascular Disorders Companies in Massachusetts, United States
The 116 best Cardiac and Vascular Disorders companies in Massachusetts, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cardurion.
Ranked: Best Cardiac and Vascular Disorders companies in Massachusetts
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cardurion Developer of therapeutics for heart and cardiovascular diseases | $270M | 23 mo ago | 34 | 2017 | — | — | — | — |
| 2 | CardioFocus Endoscopically guided catheter for ablation | $261M | 39 mo ago | 105 105 → 87 (-17%) | 1990 | — | Framer SitesReactPriority Hints+7 | 146 patents Patents concentrated in health & consumer products | 3 job openings |
| 3 | Anthos Therapeutics Developer of novel anticoagulants for thrombosis treatment | $250M | 87 mo ago | 10 | 2019 | Paris Panayiotopoulos Co-Founder | WordPressApple iCloud MailMicrosoft 365+23 | — | — |
| 4 | Verve Developer of gene-editing therapies for treating coronary artery disease | $216M | 65 mo ago | 255 | 2018 | J Joung Co-Founder | DrupalPHPAmazon Web Services+21 | 14 patents Privacy‑preserving gesture‑based demographic profiling and synthetic location generation for mobile ads | — |
| 5 | Mitralign Provider of cardiac valve repair devices | $142M | 100 mo ago | 12 | 2003 | — | — | 140 patents Percutaneous tricuspid valve repair using catheter-delivered tissue anchors and plication locks | — |
| 6 | InfoBionic AI powered remote cardiac telemetry platform for virtual care and cardiac arrhythmia management | $135M | 32 mo ago | 3 | 2011 | Stuart Long CEO | WordPress Block EditorWordPressMySQL+19 | 60 patents Remote cardiac ECG monitoring and signal quality analysis for telehealth applications. | — |
| 7 | Cellino Developer of autologous cell therapies | $125M | 21 mo ago | 43 43 → 107 (+149%) | 2017 | Matthias Wagner Co-Founder & CTO | SanityNode.jsThree.js+11 | — | 1 award |
| 8 | EarlySense Developer of smart devices for cardiac health monitoring | $124M | 89 mo ago | 53 | 2004 | Avner Halperin Co-founder and Board member | — | — | — |
| 9 | MC10 Miniaturized embedded sensors | $115M | 82 mo ago | 1 | 2008 | Ben Schlatka Co-Founder & CEO | — | 426 patents Flexible, stretchable wearable electronics with integrated circuits and encapsulated sensor modules | — |
| 10 | Arrakis Therapeutics Provider of tools for the analysis of RNA structures | $113M | 86 mo ago | 89 89 → 51 (-43%) | 2015 | Russell Petter Co-Founder & CSO | WordPressMySQLPHP+18 | — | — |
| 11 | Corvia Medical Developer of transcatheterally shunt for treating diastolic heart failure disease | $105M | 12 mo ago | 32 32 → 38 (+19%) | 2009 | George Fazio President & CEO | WordPress Block EditorWordPressMySQL+14 | — | — |
| 12 | Cheetah Medical Non-invasive cardiac output and hemodynamic monitoring device | $90M | 87 mo ago | 73 | 2001 | — | — | — | — |
| 13 | Corvidia Therapeutics Southeast Asia's leading eCommerce platform accelerating progress through commerce and technology | $86M | 97 mo ago | 9 | 2015 | — | — | — | — |
| 14 | Reprieve Cardiovascular Developer of decongestion management solution for acute decompensated heart failure patients | $84M | 10 mo ago | 16 | 2018 | — | Node.jsNextAuth.jsReact+9 | 61 patents Non‑invasive urine output monitoring and personalized fluid therapy for heart failure patients | — |
| 15 | Corsera Health Developer of technology predicting and preventing cardiovascular disease before it begins 72Funding top 24%Talent top 28%AI top 45%Global bottom 48% All 4 signals ▾Fundingtop 24% Talenttop 28% AItop 45% Globalbottom 48% Funding: Raised $80.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 72/100 | $80M | 5 mo ago | — | 2024 | Chris Cox Co-Founder | — | — | — |
| 16 | Third Pole Therapeutics Developer of devices for cardiopulmonary therapies | $73M | 27 mo ago | 73 | 2014 | — | — | — | — |
| 17 | Instylla Developer of hydrogel technology for embolization therapy | $64M | 11 mo ago | 26 | 2017 | — | WordPressApple iCloud MailMicrosoft 365+26 | — | 2 launchs |
| 18 | Elevian Developer of regenerative therapies for treating age-related diseases | $61M | 57 mo ago | 6 | 2017 | Mark Allen Co-Founder & CEO | Squarespace CommerceSquarespaceStimulus+13 | 7 patents Peptide-based pharmaceutical compositions for acute stroke treatment and neuroprotection. | — |
| 19 | Aegerion A biopharmaceutical company that develops innovative drugs to treat rare diseases | $59M | 91 mo ago | 63 | 2005 | — | — | — | — |
| 20 | Access Vascular Developer of hydrogel-based devices to improve venous access | $54M | 31 mo ago | 42 | 2015 | James Biggins President and CEO | Cart FunctionalitySquarespace CommerceSquarespace+22 | 165 patents Advanced polymeric vascular access devices and high‑strength porous biomedical materials | 1 partnership |
| 21 | Aderis Pharma Developer of small molecule drug candidates for the central nervous system, cardiovascular, and inflammatory… | $45M | 296 mo ago | 21 | 1994 | Peter Savas CEO | — | — | — |
| 22 | BG Medicine Diagnostic tests for cardiovascular disorders. | $43M | 133 mo ago | 3 | 2000 | — | — | 114 patents Galectin‑3 diagnostic assays and cardiac risk prediction biomarkers | — |
| 23 | Pervasis Therapeutics KILO303: Official site for online slot games and betting | $40M | 187 mo ago | 18 | 2003 | — | — | — | — |
| 24 | InspireMD Stents integrated with a bio-stable mesh | $34M | 10 mo ago | 66 66 → 121 (+83%) | 2005 | — | WordPressApple iCloud MailMicrosoft 365+24 | — | — |
| 25 | CoreMap Provider of platform to detect atrial fibrillation to manage heart disorders | $31M | 52 mo ago | 34 | 2017 | Sarah O'Connell Kalil CEO | Squarespace CommerceSquarespaceTypeScript+15 | 22 patents High‑resolution cardiac electrophysiology mapping and bioelectric signal analysis for diagnostics | — |
| 26 | Thermedical Developer of thermal ablation therapy for ventricular tachycardia | $28M | 33 mo ago | — | 1995 | Michael Curley Founder | — | 128 patents Catheter-based cardiac ablation devices: fluid delivery, temperature monitoring, instrument deployment | — |
| 27 | Angiolink Wound closure solutions for vascular procedures. | $28M | 153 mo ago | — | 1999 | James Lousararian Ex-CEO | — | 2 patents Patents concentrated in health & consumer products | — |
| 28 | Semprus BioSciences Provider of bio-functional medical surfaces to interface between the body and implantable devices | $26M | 176 mo ago | 13 | 2006 | — | — | 132 patents Anti‑fouling, antimicrobial and antithrombogenic surface coatings for medical devices and implants | — |
| 29 | rHEALTH Developer of portable system for a self-analysis of blood and vitals | $24M | 62 mo ago | — | 2010 | Eugene Chan Founder | WordPressMySQLPHP+19 | — | — |
| 30 | Cardiosolutions Implant to treat mitral regurgitation | $22M | 167 mo ago | 6 | 2006 | Steven Tallarida CEO | — | 108 patents Implantable cardiac valve devices and delivery catheter systems for heart valve replacement | — |
| 31 | Viacor Cathether based techniques for Heart Valve Disease | $22M | 187 mo ago | — | 1999 | A. Marc Gillinov Founder | — | 44 patents Percutaneous mitral valve repair and regurgitation reduction devices and methods | — |
| 32 | Quanttus Wearable and mobile app to monitor blood pressure | $22M | 147 mo ago | 20 | 2012 | — | — | 23 patents Non‑invasive cardiovascular biometric monitoring and calibration devices | — |
| 33 | Rhythmia Medical Medically licensed plant medicine retreat center offering holistic healing | $17M | 189 mo ago | — | 2004 | Leon Amariglio Founder & CEO | — | 138 patents Patents concentrated in health & consumer products | — |
| 34 | eXIthera Early stage biotech company focused on developing small molecule pharmaceuticals | $15M | 105 mo ago | 2 | 2012 | — | — | — | — |
| 35 | Micro Medical Solutions Developer of a device for CLI and PAD patients to prevent amputation | $13M | 7 mo ago | 13 | 2014 | Gregory Sullivan Co-Founder & CEO | — | — | — |
| 36 | Ischemia Technologies Develops, manufactures, and markets in vitro diagnostic tests for cardiac ischemia | $13M | 279 mo ago | — | 1997 | James Weersing CEO | — | — | — |
| 37 | HeartWare Global healthcare technology company specializing in medical devices and therapies | $12M | 200 mo ago | 506 | 2005 | — | — | 1,058 patents Implantable ventricular assist blood pumps and associated patient monitoring/control systems | — |
| 38 | Saphena Medical Endoscopic vessel harvesting for cardiovascular procedures | $12M | 44 mo ago | 10 | 2013 | — | — | — | — |
| 39 | Ingenia Therapeutics Provider of healthcare therapeutic services | $12M | 24 mo ago | — | 2018 | Sangyeul Han Founder & CEO | Apple iCloud MailPHPApache HTTP Server+11 | — | — |
| 40 | Medwave Developer of medical device for monitoring of blood pressure. | $11M | 243 mo ago | — | 1984 | Tim Malley CEO | — | 7 patents Non‑invasive blood pressure estimation and continuous monitoring technologies | — |
| 41 | AUM Cardio Device to detect coronary artery blockage | $11M | 114 mo ago | 13 | 2009 | — | — | — | — |
| 42 | CorNova Range of endovascular products | $11M | 185 mo ago | 2 | 2003 | — | — | 76 patents Endoscopic fluid delivery and diagnostic/therapeutic systems for body lumens | — |
| 43 | SmartPharm Therapeutics Developer of biologics for treating cardiovascular diseases | $11M | 86 mo ago | 7 | 2017 | — | — | — | — |
| 44 | TenSixty Biosciences Developer of therapeutics for cancer and cardiovascular disease | $7M | 45 mo ago | — | 2022 | Daniel Montoro CEO | — | — | — |
| 45 | MiRTLE Medical Provider of MRI-compatible 12-lead ECG monitoring system | $5M | 12 mo ago | 2 | 2012 | — | — | — | — |
| 46 | Agile Devices Medical device that assists with peripheral and coronary vascular treatment | $3M | 18 mo ago | 8 | 2014 | — | — | — | — |
| 47 | Bloomer Tech Smart innerwear for cardiac monitoring | $3M | 34 mo ago | 11 | 2015 | Alicia Chong Rodriguez Co-Founder & CEO | — | — | — |
| 48 | Transmural Systems Pioneering electrosurgical therapies to redefine care for structural heart failure | $3M | 13 mo ago | 13 | 2014 | — | — | — | — |
| 49 | Dynocardia.Care Provider of wearable devices for remote monitoring solutions | $2M | 13 mo ago | 12 | 2018 | — | Cart FunctionalitySquarespace CommerceSquarespace+10 | — | — |
| 50 | RNatives Developer of RNA-based treatments for cardiovascular diseases | $2M | 12 mo ago | 5 | 2021 | — | — | 2 patents Synthetic microRNA mimic design and production for gene regulation therapies | 1 internship |
Top 12 Cardiac and Vascular Disorders companies in Massachusetts
#1
Series A · Boston, Massachusetts · founded 2024$80Mraised▾
Developer of technology predicting and preventing cardiovascular disease before it begins. The company utilizes science and artificial intelligence for cardiovascular wellness. It aims to empower people to live healthier and longer lives.
- Jan 2026Series A$80M
#2
Series B · Milford, Massachusetts · founded 2018 · 16 employees$84Mraised▾
Developer of decongestion management solution for acute decompensated heart failure patients. The company's technology combines real-time patient data with automated diuretic therapy to safely accelerate fluid removal, addressing limitations of traditional diuretics.
- Aug 2025Conventional Debt—
- May 2025Series B$61M
- Sep 2024Series A$9.5M
- Feb 2024Series A$42M
#3
Acquired · Tewksbury, Massachusetts · founded 2009 · 32 employees$105Mraised▾
Developer of transcatheterally shunt for treating diastolic heart failure disease. The InterAtrial Shunt Device (IASD) is designed to reduce elevated left atrial pressure which is the main cause of the symptoms of heart failure. The device provides continuous decompression of the left atrium at rest and during activity in order to reduce symptoms and slow the progression of diastolic heart failure.
- Jun 2025Series D$55M
- Jun 2022Series C$54M
- Jan 2021Series B$6.3M
- Sep 2015Series B$34M
#4
Series B · Massachusetts · founded 2017 · 26 employees$63.8Mraised▾
Developer of hydrogel technology for embolization therapy. The company delivers next-generation liquid embolics for interventional radiology, with initial clinical applications in interventional oncology and peripheral hemostasis.
- Jul 2025Series B$21.7M
- Aug 2023Series B$30.3M
- Oct 2020Series B$25.4M
- Jun 2017Series A$8.1M
#5
Public · Boston, Massachusetts · founded 2005 · 66 employees$34Mraised▾
InspireMD, a medical device company, develops and commercializes its proprietary stent system technology. The company has developed, MicroNet, a bio-stable mesh woven from a single strand of 20 μm Polyethylene Terephthalate (PET). It is designed to trap and seal thrombus and plaque against the vessel wall, preventing embolization. Using their MicroNet technology they have developed CGuard and MGuard Embolic Protection System. Its MGuard and MGuard Prime products are indicated for providing embolic protection in patients undergoing primary or rescue PCI for acute ST-segment elevation myocardial infarction (STEMI) or in patients with non ST-elevation acute coronary syndromes (unstable angina and non ST-segment elevation myocardial infarction), and in cases of symptomatic coronary artery disease (CAD) due to a discrete de novo or restenotic lesion in a native coronary artery or a culprit lesion in a saphenous vein graft. CGuard Carotid Stent System is indicated for improving carotid luminal diameter in patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization.
- Jul 2025Post IPO$40.1M
- May 2023Post IPO$42.2M
- Dec 2017Post IPO$750K
- Jun 2016Post IPO$182.4K
#6
Series B · Wilmington, Massachusetts · founded 2014 · 13 employees$13Mraised▾
Developer of a device for CLI and PAD patients to prevent amputation. The company develops minimally invasive tools for microvascular intervention. The company's products MicroStent, a vascular stent specifically designed to reduce below-the-knee amputations for critical limb ischemia (CLI) resulting from peripheral artery disease.
- Oct 2025Series B$2.3M
- Jul 2025Series B$2.5M
- Oct 2022Conventional Debt$2.2M
- Oct 2021Conventional Debt$1.3M
#7
Series B · Boston, Massachusetts · founded 2017 · 34 employees$270Mraised▾
Developer of therapeutics for heart and cardiovascular diseases. The propriety CRD-733, a PDE-9 inhibitor helps to improve cardiac function in heart failure patients and improves dysfunction in heart failure. The company is in its clinical stage of cardiovascular drug programs.
- Jul 2024Series B$260M
- Dec 2022Conventional Debt$17.5M
- Oct 2021Series B—
- Nov 2019Series A$10M
#8
Series A · Cambridge, Massachusetts · founded 2017 · 43 employees$125Mraised▾
Developer of autologous cell therapies. The company has developed an AI-guided laser editing platform, single-cell laser processing, and robotics to generate autologous induced pluripotent stem cells for regenerative medicines for diseases like Parkinson’s, diabetes, and heart disease.
- Sep 2024Series A$25M
- Jan 2022Series A$80M
- Feb 2021Seed$16M
- Aug 2019Seed$2.5M
#9
Series A · North Andover, Massachusetts · founded 2012 · 2 employees$4.8Mraised▾
Provider of MRI-compatible 12-lead ECG monitoring system. The device performs with interference-free ECG signals to a cardiologist and gates the MRI during a heartbeat, thereby enabling the MRI to produce sharp images of the heart. It can be used in Ablation for arrhythmia, Targeted chemotherapy, and Tumor removal.
- 2025Series A$610K
- Jun 2025Series A$610K
- Feb 2025Series A$405K
- May 2023Series A$2.1M
#10
Series A · Cambridge, Massachusetts · founded 2018 · 12 employees$1.6Mraised▾
Provider of wearable devices for remote monitoring solutions. The company develops ViTrack, which is wearable technology that helps in monitoring blood pressure and other body vitals to give real-time insights for practitioners to manage patient's health. The company focuses on managing hypertension, dementia, sleep apnea, and more.
- May 2025Grant (prize money)$2.4M
- Mar 2025Series A$1.2M
- Sep 2023Grant (prize money)$2.4M
- Mar 2023Series A$4.8M
#11
Funding Raised · Andover, Massachusetts · founded 2014 · 13 employees$2.5Mraised▾
Pioneering electrosurgical therapies to redefine care for structural heart failure. This clinical-stage medical device company is dedicated to developing innovative electrosurgical therapies. They aim to transform the treatment landscape for structural heart failure. Their focus is on creating advanced medical devices that offer improved patient outcomes. They are committed to advancing the field of cardiac care through cutting-edge technology. This involves research, development, and clinical trials to bring novel solutions to market. Their work has a direct social impact by improving the lives of individuals suffering from heart conditions. They are not a tech company, SaaS, or software provider, but rather a medical device innovator.
- Apr 2025Grant (prize money)$2.5M
#12
Series B · Boston, Massachusetts · founded 2014 · 73 employees$73Mraised▾
Developer of devices for cardiopulmonary therapies. The company is developing a device offering nitric oxide (NO) from iridium electrodes for infant acute pulmonary hypertension, heart, and lung therapies. The inhaled nitric oxide therapy delivery system relaxes the blood vessels lowering the blood pressure.
- Mar 2024Series B$16.9M
- Dec 2022Series B$32M
- Feb 2022Series B$25M
- Apr 2021Conventional Debt$15M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.